Unknown

Dataset Information

A novel 4-gene prognostic signature for hypermutated colorectal cancer.


ABSTRACT:

Background

Hypermutated colorectal cancer (CRC) reportedly accounts for 15%-17% of all cases of CRC. However, the proportion and number of patients with hypermutated CRC cannot be unappreciated. Additionally, therapy options for these patients differ from those for CRC patients, with a greater potential benefit from immunotherapy.

Materials and methods

We sequenced the tumor mucosa of CRC patients with >24 months of follow-up data at our center and identified mutation profiles of hypermutated CRC as a training data set (Zhejiang University [ZJU]); we then collected patients from The Cancer Genome Atlas (TCGA) as a validation data set. Recurrently mutated genes were combined to calculate a compound score via Cox proportional hazards model. Patients with higher-than-median sco

SUBMITTER: Ge W 

PROVIDER: S-EPMC6407520 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature